ArticleInternational journal of molecular sciences2020
4,4'-Diaminodiphenyl Sulfone (DDS) as an Inflammasome Competitor.
Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 49 citations in OpenAlex.
- Bronchitis, COPD, and pneumonia after viral endemic of patients with leprosy on Sorok Island in South Korea.Naunyn-Schmiedeberg's archives of pharmacology · 2023Trial
- Targeting Leukopoiesis: Pharmacological and Biotechnological Strategies for the Treatment of Leukopenia.Biomedicines · 2026Review
- A Comprehensive Review of Acne Treatments: Unpacking the Chemical Structures and Effective Bioactive Compounds.Health science reports · 2026Article
- Acute anticonvulsant effects of dapsone on PTZ- and MES-induced seizures in mice: NLRP3 inflammasome inhibition and Nrf2/HO-1 pathway preservation.Pharmacological reports : PR · 2025Article
- Basic implications on three pathways associated with SARS-CoV-2.Biomedical journal · 2025Review
- The antifibrotic effect of Vildagliptin and Diaminodiphenyl Sulfone in murine schistosomiasis mansoni.Scientific reports · 2025Article
- Article
- The Potential Effect of Dapsone on the Inflammatory Reactions in COVID-19: Staggering View.Combinatorial chemistry & high throughput screening · 2024Review
- Development of a multivariate predictive model for dapsone adverse drug events in people with leprosy under standard WHO multidrug therapy.PLoS neglected tropical diseases · 2024Article
- Myeloperoxidase in Health and Disease.International journal of molecular sciences · 2023Article
- Treatment mechanism of immune triad from the repurposing drug against COVID-19.Translational medicine of aging · 2023Review
- COVID-19 Molecular Pathophysiology: Acetylation of Repurposing Drugs.International journal of molecular sciences · 2022Review
- Article
- The listed, delisted, and sustainability of therapeutic medicines for dementia patients: the study is specific to South Korea.Naunyn-Schmiedeberg's archives of pharmacology · 2022Article
- Article
- Dapsone, More than an Effective Neuro and Cytoprotective Drug.Current neuropharmacology · 2022Review
- Specific Treatment Exists for SARS-CoV-2 ARDS.Vaccines · 2021Article
- Research Supporting a Pilot Study of Metronomic Dapsone during Glioblastoma Chemoirradiation.Medical sciences (Basel, Switzerland) · 2021Article
- Drug repurposing of dermatologic medications to treat coronavirus disease 2019: Science or fiction?Clinics in dermatologyArticle
- Commentary for the Elderly in the Pandemic Era.Dementia and geriatric cognitive disorders extraArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study is to examine the use of an inflammasome competitor as a preventative agent. Coronaviruses have zoonotic potential due to the adaptability of their S protein to bind receptors of other species, most notably demonstrated by SARS-CoV. The binding of SARS-CoV-2 to TLR (Toll-like receptor) causes the release of pro-IL-1β, which is cleaved by caspase-1, followed by the formation and activation of the inflammasome, which is a mediator of lung inflammation, fever, and fibrosis. The NLRP3 (NACHT, LRR and PYD domains-containing protein 3) inflammasome is implicated in a variety of human diseases including Alzheimer's disease (AD), prion diseases, type 2 diabetes, and numerous infectious diseases. By examining the use of 4,4'-diaminodiphenyl sulfone (DDS) in the treatment of patients with Hansen's disease, also diagnosed as Alzheimer's disease, this study demonstrates the diverse mechanisms involved in the activation of inflammasomes. TLRs, due to genetic polymorphisms, can alter the immune response to a wide variety of microbial ligands, including viruses. In particular, TLR2Arg
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.